%0 Journal Article %A YOSUKE MORODOMI %A MITSUHIRO TAKENOYAMA %A EIKO INAMASU %A RYO TOYOZAWA %A MIYAKO KOJO %A GOUJI TOYOKAWA %A YOSHIMASA SHIRAISHI %A TOMOYOSHI TAKENAKA %A FUMIHIKO HIRAI %A MASAFUMI YAMAGUCHI %A KENICHI TAGUCHI %A TAKASHI SETO %A KENJI SUGIO %A YUKITO ICHINOSE %T Non-small Cell Lung Cancer Patients with EML4-ALK Fusion Gene Are Insensitive to Cytotoxic Chemotherapy %D 2014 %J Anticancer Research %P 3825-3830 %V 34 %N 7 %X Background: Although patients with the echinoderm microtubule-associated protein-like 4–anaplastic lymphoma kinase gene (EML4-ALK) re-arrangement and epidermal growth factor gene EGFR mutations have proven sensitive to specific inhibitors, there is currently no consensus regarding the sensitivity of non-small cell lung cancer (NSCLC) patients with such mutations to cytotoxic chemotherapy. Patients and Methods: The responses to first-line cytotoxic chemotherapy were retrospectively compared between advanced or postoperative recurrent patients with non-squamous NSCLC who harbor the EML4-ALK fusion gene (ALK+), EGFR mutation (EGFR+), or neither abnormality (wild-type). Results: Data for 22 ALK+, 30 EGFR+, and 60 wild-type patients were analyzed. The ALK+ group had a significantly lower response rate than the other two groups. Progression-free survival was significantly shorter in the ALK+ cohort compared to the EGFR+ (p<0.001) and wild-type cohorts (p=0.0121). Conclusion: NSCLC patients with the EML4-ALK fusion gene might be relatively insensitivite to cytotoxic chemotherapy. %U https://ar.iiarjournals.org/content/anticanres/34/7/3825.full.pdf